RBC Capital Upgrades Sagent Pharmaceuticals (SGNT) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sagent Pharmaceuticals (SGNT) Numbers Cut at Piper Jafffray Post Q2
August 5, 2015 9:47 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $32.00 (from $35.00) following Q2 results but maintained an Overweight rating.
Amsellem commented, "This morning, Sagent reported a 2Q15 net loss per share of ($0.01), compared to the Street EPS... More
Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c
August 4, 2015 8:54 AM EDTSagent Pharmaceuticals (NASDAQ: SGNT) reported Q2 EPS of ($0.01), $0.06 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $83.28 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.
... More